STERIS plc provides infection prevention and other procedural products and services worldwide.
$252.30-0.72%
报价 2026-11-06
市值
$24.6B
EV
$26.12B
PE (TTM)
29.9x
预期 PE (FY2027)
22.5x
52 周区间距高点 -6.1%
$199.40$268.65
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Devices| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STESTERIS plc | $24.6B | -0.7% | +7.3% | 44.7% | 29.9x | 17.0x | 26.3x | |
| EWEdwards Lifesciences Corporation | $58.87B | +1.3% | +11.8% | 78.1% | 44.5x | 32.6x | 44.1x | GARP |
| PHGKoninklijke Philips N.V. | $29.66B | -0.5% | – | 45.2% | 24.5x | 10.1x | – | |
| DXCMDexCom, Inc. | $29.62B | -6.0% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| ZBHZimmer Biomet Holdings, Inc. | $20.14B | -1.2% | +4.7% | 71.2% | 26.6x | 11.9x | 12.2x | |
| SNNSmith & Nephew plc | $13.41B | -2.7% | – | 68% | 22.0x | 10.3x | – | |
| GKOSGlaukos Corporation | $13.28B | +2.0% | +56.0% | 85.2% | – | – | 368.8x | 高增长 |
| PENPenumbra, Inc. | $12.58B | -0.6% | +15.2% | 67.1% | 74.0x | 59.0x | 71.8x | |
| ALGNAlign Technology, Inc. | $11.79B | +4.2% | +2.7% | 68.7% | 24.1x | 14.5x | 16.7x | |
| 同行中位数 | – | – | +12.1% | 68.4% | 26.6x | 14.5x | 34.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q2 2027 | 2026-06-30 Q1 2027 | 2026-03-31 Q4 2026 | 2025-12-31 Q3 2026 | 2025-09-30 Q2 2026 | 2025-06-30 Q1 2026 | 2025-03-31 Q4 2025 | 2024-12-31 Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59B | $1.49B | $1.59B | $1.5B | $1.46B | $1.39B | $1.48B | $1.37B |
| Gross Margin | 44.7% | 45.8% | 43.9% | 43.8% | 44.2% | 45.1% | 43.3% | 44.5% |
| Operating Margin | 18.5% | 19.1% | 19.9% | 18.1% | 18.4% | 17.7% | 14.6% | 17.9% |
| Net Income | $213.7M | $200.1M | $220.3M | $192.8M | $191.9M | $177.4M | $145.7M | $173.5M |
| Diluted EPS | 2.19 | 2.04 | 2.24 | 1.96 | 1.94 | 1.79 | 1.48 | 1.75 |
| Operating Cash Flow | $288.8M | $367.1M | $335.4M | $298.2M | $287.8M | $420M | $260.8M | $332.8M |